Latest news with #ChadWatkins
Newsweek
4 days ago
- Science
- Newsweek
US Intelligence Flight Detected on China's Doorstep
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A United States military aircraft designed to gather radar signals was detected flying deep in the contested South China Sea on Tuesday, publicly available flight data showed. Newsweek reached out to the Chinese Defense Ministry and U.S. Pacific Air Forces via email for comment outside of office hours. Why It Matters The Pentagon typically does not disclose specifics about its military operations, but a U.S. Air Force fact sheet says the Combat Sent collects "strategic electronic reconnaissance information" for decision makers in the U.S. military chain of command. "Locating and identifying foreign military land, naval and airborne radar signals, the Combat Sent collects and minutely examines each system, providing strategic analysis for warfighters," the Air Force said, in a description of the platform's role in developing effective anti-radar countermeasures such as jamming. What To Know The RC-135U, also known as the Combat Sent, probed the waters around the disputed Spratly and Paracel islands in a 10-hour flight from a major military hub in southwestern Japan, according to self-reported geodata recorded by the website Flightradar24. The August 6 flight was first spotted by open-source intelligence analyst MeNMyRC1, a former RC-135 crew member and signals intelligence platform specialist. They said it was unusual for U.S. spy flights to be seen so far south in the South China Sea, while noting that the area often lacks enough ground receivers to pick up aircraft tracks. The Combat Sent, which was deployed in late June from the continental United States to Kadena Air Base on the Japanese island of Okinawa, flew its latest sortie just after 6 a.m. universal coordinated time, or UTC, according to Flightradar24. It did not land until after 4 p.m. UTC the same day. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base in Nebraska on March 31, 2025. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base in Nebraska on March 31, 2025. Chad Watkins/U.S. Air Force Flight records showed the Combat Sent has been deployed on suspected electronic intelligence-gathering flights at least 11 times since July 1, probing contested areas including just south of the North Korean border as well as near China's southernmost province of Hainan, home to one of the Chinese navy's aircraft carriers stationed in the South China Sea. The Air Force says the Combat Sent aircrew includes "a minimum of 10 electronic warfare officers…and six or more mission area specialists." The plane has a fuel range of over 4,500 miles and an operational ceiling higher than 35,000 feet. The U.S. military has two Combat Sent platforms in operation. They first flew in the mid-1960s and are expected to remain in service until the 2040s. Beijing-based think tank the South China Sea Strategic Situation Probing Initiative wrote on X that it had tracked 48 sorties by U.S. spy planes over the South China Sea in July alone, four of which were RC-135s. China claims sovereignty over the Spratly archipelago off the west coast of the Philippines and has controlled the Paracel group east of Vietnam since the mid-1970s. In both sets of disputed islands, China has artificially expanded shoals and reclaimed reefs to create large military bases housing radars, barracks and airfields. What People Are Saying Chinese Foreign Ministry spokesperson Mao Ning told reporters on February 9: "US aircraft and warships frequently conduct close-in reconnaissance around China, which seriously threatens China's national security and undermines regional peace and stability. What Happens Next Both the U.S. and Chinese militaries are expected to continue deploying surveillance planes in the western Pacific.
Newsweek
16-07-2025
- Politics
- Newsweek
U.S. Spy Plane Tracked Near Iran
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A U.S. Air Force Rivet Joint surveillance aircraft was spotted flying from a military base in the Middle East over the Persan Gulf near Iran, flight tracking data shows. Newsweek has reached out to the Pentagon and the Iranian Foreign Ministry for comment. Why It Matters The Rivet Joint's tracked flight over the Persian Gulf shows the deployment of manned surveillance aircraft alongside the long-standing reliance on drones to monitor Iran following a 12-day conflict with Israel during which the U.S. bombed major nuclear facilities. The U.S. seeks to expand intelligence in the region given rivalries involving Iran, China, and Russia and security challenges that include nuclear developments in Iran, maritime security challenges and increased monitoring of China's expanding military activities in the Indo-Pacific region. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base on March 31, 2025. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base on March 31, 2025. Chad Watkins/U.S. Air Force What To Know The Boeing RC-135V Rivet Joint that flew a mission over the Persian Gulf operated out of Al-Udeid Air Base in Qatar, the largest U.S. air force base in the region. The aircraft departed its home base at Offutt Air Force Base near Omaha, Nebraska, on Friday. It then transited through RAF Mildenhall in the United Kingdom on Monday, before arriving in Qatar on Wednesday, flight data from Flightradar24 showed. The Rivet Joint is a Boeing plane with a crew of over 30 that can gather signals intelligence. Tensions remain high in the region despite a truce between Iran and Israel. Iran said Wednesday it seized a foreign oil tanker in the Sea of Oman, suspected of carrying around 2 million liters of smuggled fuel. Rivet Joint 64-14846 on its first mission over the Persian Gulf after arriving 2 days ago. Nice tracking today after they have been flying with transponders in a tactical mode. — MeNMyRC (@MeNMyRC1) July 16, 2025 The U.S. conducted two similar surveillance missions near Russian territory, with an RC-135V Rivet Joint departing from a British air base on Tuesday and flew through allied European airspace. China, which is rapidly expanding its military, remains a key surveillance target for the United States. Beijing has repeatedly protested against what it describes as "close-in reconnaissance" near its coastline — operations that have, at times, led to tense or dangerous encounters between U.S. and Chinese aircraft. While Iran has said it would be prepared for talks, it has also rejected U.S. demands that it stop uranium enrichment and has threatened to enrich up to bomb grade levels if European countries impose new sanctions. Iran denies seeking nuclear weapons. The disagreement has raised the prospect of further military action if no deal can be reached and if Iran pushed ahead further with its nuclear program. What People Are Saying US President Donald Trump: "They [Iran] would like to talk. I'm in no rush to talk because we obliterated their site." Iran's Supreme Leader Ali Khamenei: "We entered the war with strength. The proof for this is that the Zionist regime was compelled to turn to the US for help. If it had been capable of defending itself, it wouldn't have turned to the US like that. It turned to the US for help... The US attacked Iran, and our retaliatory strike against it was very significant. God willing, once censorship is removed, it will become clear what Iran has truly done." What Happens Next The situation is likely to remain tense in the Middle East while there is no agreement over Iran's nuclear program. European countries and the United States have set a deadline of August.
Newsweek
10-06-2025
- General
- Newsweek
Photos Reveal US Air Force Spying Capabilities
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Recently released photos show a fleet of specialized United States military aircraft staged on a flight line, highlighting their capabilities for a wide range of intelligence-gathering missions. The 55th Wing of the U.S. Air Force, an intelligence, surveillance, and reconnaissance unit headquartered at Offutt Air Force Base in Nebraska, told Newsweek in a statement that its aircraft and personnel conduct missions that defend the U.S. and safeguard global security. Why It Matters The U.S. Air Force often deploys its reconnaissance aircraft overseas to gather intelligence on America's adversaries. Forward deployment locations include Kadena Air Base in Japan, Royal Air Force Mildenhall in the United Kingdom, and Al Udeid Air Base in Qatar. American spy flights off the coasts of Russia and China have been intercepted by Russian and Chinese fighter jets. Moscow has stated it will not allow its borders to be violated, while Beijing has accused Washington of conducting "close-in reconnaissance" near its territory. Several U.S. Air Force RC-135V/W Rivet Joint aircraft park on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. Several U.S. Air Force RC-135V/W Rivet Joint aircraft park on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. Chad Watkins/U.S Air Force What To Know A set of seven photos released by the 55th Wing over the weekend shows several U.S. Air Force aircraft parked on the flightline at Offutt Air Force Base at night on June 1. These aircraft included the RC-135U Combat Sent, the RC-135V/W Rivet Joint, and the WC-135 Constant Phoenix. They are developed from the C-135 Stratolifter transport aircraft. The Combat Sent can locate and identify foreign military radar signals, while the Rivet Joint detects, identifies, and geolocates electromagnetic signals. The Constant Phoenix conducts air-sampling missions, collecting particulates in the air for detecting nuclear explosions. A U.S. Air Force RC-135U Combat Sent aircraft, right, parks on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. A U.S. Air Force RC-135U Combat Sent aircraft, right, parks on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. Chad Watkins/U.S. Air Force In the statement, the 55th Wing stated that the unit has global reach and enduring strategic impact by maintaining forward-deployed units around the globe, ensuring what it described as "rapid and persistent global ISR [intelligence, surveillance, and reconnaissance] coverage." In addition to the aforementioned specialized aircraft, the Nebraska-based unit operates the so-called "rapidly deployable" RC-135S Cobra Ball, which is designed for collecting data on ballistic missiles, a vital information that cannot be obtained by "any other source." What People Are Saying The 55th Wing of the U.S. Air Force, in a statement to Newsweek: "While we do not disclose operational status or comment on specific interactions with foreign military aircraft for operational security, the 55th Wing remains steadfast in executing its mission with precision, professionalism, and strict adherence to international standards." Offutt Air Force Base, on its website: "[The 55th Wing's] mission is to provide dominant information warfare forces through electromagnetic spectrum operations, information operations, intelligence, surveillance, reconnaissance, and nuclear command, control and communications to the Joint Forces and national leadership, any time, any place." Two U.S. Air Force WC-135 Constant Phoenix aircraft, left and center, and an RC-135U Combat Sent aircraft park on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. Two U.S. Air Force WC-135 Constant Phoenix aircraft, left and center, and an RC-135U Combat Sent aircraft park on the flight line at Offutt Air Force Base in Nebraska on June 1, 2025. Chad Watkins/U.S. Air Force What Happens Next It remains to be seen how the U.S. military maintains its worldwide airborne spying missions amid tensions on the Korean Peninsula, across the Taiwan Strait, and in the Middle East.
Yahoo
29-04-2025
- Business
- Yahoo
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)1 for gallium-68 production using its QUANTM Irradiation System® (QIS®) cyclotron technology has been referenced for the first time with a United States (U.S.) Food and Drug Administration (FDA) approved product, with Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection). This approval will enable radiopharmacies and hospitals using ARTMS' QIS® cyclotron technology and associated targets to produce multi-Curies of 68Ga for use with Gozellix®. The expanded distribution radius and increased dose production capacity, compared to existing gallium-based PET tracers, will facilitate broader and more equitable access. In addition, use of ARTMS' technology is being expanded internationally where regulatory submissions are in preparation. Pharmaceutical companies will be able to reference ARTMS' standardized isotope production technology with their approved drugs, helping to localize and simplify manufacturing. Chad Watkins, General Manager ARTMS and Isotope Strategy, Telix, said, 'This DMF reference represents a significant milestone for ARTMS, our partners and customers. The combination of these innovative technologies reflects Telix's commitment to working in partnership to reach more patients with 68Ga-PSMA-11, where and when they need it.' The QIS® forms part of ARTMS' 'turnkey' solution for customers that encompasses in-house manufactured targets and chemistry processing of isotopes, as well as DMF preparation and filing support. This makes large scale isotope production for hospitals and radiopharmaceutical distributors with cyclotrons significantly more attainable than with other existing technologies. ARTMS will continue to support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS' portfolio of advanced cyclotron technologies has application for Telix and select partners in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At). For further information please contact: Chad Watkins Telix Pharmaceuticals LimitedGeneral Manager of ARTMS & Isotope StrategyEmail: Kevin ReimerTelix ARTMS, Global Sales and MarketingEmail: About Telix ARTMS, Inc. Based in Burnaby, British Columbia, Canada, Telix ARTMS, Inc. (ARTMS) is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world's most-used diagnostic imaging isotopes. ARTMS' flagship product, the QUANTM Irradiation System® (QIS®), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS was acquired by Telix Pharmaceuticals in April 20242. For more information on QIS® and ARTMS, please follow us on X @ARTMS_TLX and LinkedIn and visit About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA3. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: Legal Notices You should read this announcement together with Telix risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _______________________ 1 A DMF is a submission to FDA used to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products.2 Telix ASX disclosure 11 April 2024.3 Telix ASX disclosure 21 March in to access your portfolio
Yahoo
12-03-2025
- Business
- Yahoo
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production. The new generator technology, developed internally by Telix's IsoTherapeutics team, produces 212Pb via a sealed Thorium-228 (228Th) source, and significantly increases the amount of radioactivity, yield and shelf life compared to currently available 212Pb generators. The fully automated, high-output generators have a small, single hot cell footprint and produce sufficient 212Pb elution for up to 60 clinical doses, with the potential to further scale. The production footprint has been designed to be deployed throughout Telix's (and select partner) manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies network. This development builds on Telix's extensive experience with developing generator-based radiopharmaceutical products. The novel technology opens new opportunities for the development of alpha-emitting radiopharmaceuticals for use in Telix's next-generation therapeutics pipeline. Lead-212 is a promising isotope for Targeted Alpha Therapy (TAT) but its relatively short half-life (10.6 hours, compared with 9.9 days for actinium-225, 225Ac) and lack of production scale has limited commercial potential. The alpha-emitting profile of 212Pb also has practical synergies with engineered antibodies being developed using Telix's newly acquired discovery platform[1], with pharmacology and clearance organ characteristics that are well suited to its short half-life. Chad Watkins, General Manager, Isotope Strategy, Telix, said, "A lead-212 generator that produces minimal waste and fits within the current radiopharmacy footprint is a step change in the production of this alpha emitting therapeutic radioisotope. It creates the potential for commercial scale lead-212 isotope production that wasn't possible before and opens up new pathways for matching this promising alpha isotope with a range of targeting agents." About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Telix ASX disclosure 31 January 2025. View original content to download multimedia: SOURCE Telix Pharmaceuticals Limited
